The influence of peripheral arterial disease on lower limb surface myoelectric signals in patients living with type II diabetes mellitus

Bartolo, Erica; Thorne, Claire Saliba; Gatt, Alfred; Formosa, Cynthia

doi:10.1016/j.gaitpost.2019.07.254

Cited by 6 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding appears to be in contradiction with the reductions in moment at the ankle and knee reported by Koutakis et al [11,12]. A similar contradiction appears between kinetic and kinematic studies and Bartolo et al (2019) who identified an increase in EMG muscle activity in many major lower limb muscles including the gastrocnemius and tibialis anterior [14]. In stationary studies, King et al (2015) identified that the soleus muscle contributes more to plantarflexion in both claudicating and asymptomatic limbs of individuals with PAD-IC compared to controls [15].…”

Section: Introductionmentioning

confidence: 84%

“…A similar contradiction appears between kinetic and kinematic studies and Bartolo et al (2019) who identified an increase in EMG muscle activity in many major lower limb muscles including the gastrocnemius and tibialis anterior [14]. In stationary studies, King et al (2015) identified that the soleus muscle contributes more to plantarflexion in both claudicating and asymptomatic limbs of individuals with PAD-IC compared to controls [15]. Although this is supported by muscle fibre changes observed in this group, it still does not provide a direct link to the kinetic results observed in other studies.…”

Section: Introductionmentioning

confidence: 94%

See 1 more Smart Citation

Effects of intermittent claudication due to arterial disease on pain-free gait

Evangelopoulou

Jones

Jameel

et al. 2021

Clinical Biomechanics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 84%

Section: Introductionmentioning

confidence: 94%

Effects of intermittent claudication due to arterial disease on pain-free gait

Evangelopoulou

Jones

Jameel

et al. 2021

Clinical Biomechanics

View full text Add to dashboard Cite

“…Data extraction led to the evaluation of 140 publications, of which 87 met the inclusion criteria, and 79 were included in the final review. Of these, 18 gave sufficient data for epidemiological analysis and diagnostic criteria, [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] 33 gave sufficient data for mechanistical analysis, and 28 gave sufficient data for therapeutic approaches. 1/Epidemiological data: Is sarcopenia a rare condition in patients with PAD?…”

Section: Resultsmentioning

confidence: 99%

“…Indeed, Bartolo et al recently showed a significant increase in the electromyogram muscle amplitude of PAD and diabetic patients, characteristic of less efficient lower muscle contractions and probable early fatigue. 11 Thus, skeletal muscle wasting is exacerbated in PAD patients presenting with a metabolic syndrome. Such patients represent a particularly fragile population that requires specific attention because of prominent atherosclerotic risk factors and poor outcomes.…”

Section: Resultsmentioning

confidence: 99%

Sarcopenia and peripheral arterial disease: a systematic review

Pizzimenti

Meyer

Charles

et al. 2020

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Patients with lower extremity peripheral arterial disease (PAD) and sarcopenia are a population at risk requiring specific and targeted care. The aim of this review is to gather all relevant studies associating sarcopenia and PAD and to identify the underlying pathophysiological mechanisms as well as potential therapeutic strategies to improve skeletal muscle function. Methods A systematic review was carried out following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results Data extraction allowed the evaluation of 140 publications; 87 met the inclusion criteria; of which 79 were included in the final review, reporting sufficient data for epidemiological and diagnostic criteria, mechanical analysis, and therapeutic approaches. Epidemiological analysis and diagnostic criteria were based on 18 studies following 2362 PAD patients [31.39% (SD 7.61) women], aged 72.42 (SD 2.84); sarcopenia was present in 34.63% (SD 12.86) of the patients. Mechanical and pathway analysis were based on five animal studies and 29 clinical reports, showing significantly altered muscle strength and function in 1352 PAD patients [26.49% (SD 17.32) women], aged 67.67 (SD 5.14) years; impaired muscle histology in 192 PAD patients (9.2% (SD 11.22) women), aged 64.3 (SD 0.99) years; +58.63% (SD 25.48) of oxidative stress in 69 PAD patients [16.96% (SD 8.10) women], aged 63.17 (SD 1.43) years; mitochondriopathy in 153 PAD patients [29.39% (SD 28.27) women], aged 63.50 (SD 1.83) years; +15.58% (SD 7.41) of inflammation in 900 PAD patients [40.77% (SD 3.71) women], aged 74.88 (SD 2.76) years; and altered signalling pathways in 51 PAD patients [34.45% (SD 32.23) women], aged 72.25 (SD 5.25) years. Therapeutic approaches analysis was based on seven animal studies and 21 clinical reports. In total, 884 patients followed an exercise therapy, and 18 received an angiogenesis treatment; 30.84% (SD 17.74) were women. Mean ages of patients studied were 66.85 (SD 3.96). Conclusions Sarcopenia and lower extremity PAD have musculoskeletal consequences that directly impair patients' quality of life and prognosis. Although PAD is primarily a vascular disease, all etiological factors of sarcopenia identified so far are present in PAD. Indeed, both sarcopenia and PAD are accompanied by oxidative stress, skeletal muscle mitochondrial impairments, inflammation, inhibition of specific pathways regulating muscle synthesis or protection (i.e. IGF-1, RISK, and SAFE), and activation of molecules associated with muscle degradation. To date, besides revascularization, the best therapeutic strategy includes exercise, but approaches targeting the underlying mechanisms still deserve further studies.

show abstract

“…Although the current pharmacological treatments and surgical procedures have improved the survival rate of the patients with cardiac disease, none of these therapies mentioned above can replace the cardiac tissue lost after infarction (Calin et al, 2013). Peripheral vascular disease (PVD), which is characterized by the narrowing of the peripheral vasculature, has a significant unfavorable impact on the health of patients (Bartolo et al, 2019). However, traditional strategies have limited efficacy in treating PVD (Tu et al, 2015;Hedhli et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

The Roles of Nanoparticles in Stem Cell-Based Therapy for Cardiovascular Disease

Sun

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is currently one of the primary causes of mortality and morbidity worldwide. Nanoparticles (NPs) are playing increasingly important roles in regulating stem cell behavior because of their special features, including shape, size, aspect ratio, surface charge, and surface area. In terms of cardiac disease, NPs can facilitate gene delivery in stem cells, track the stem cells in vivo for long-term monitoring, and enhance retention after their transplantation. The advantages of applying NPs in peripheral vascular disease treatments include facilitating stem cell therapy, mimicking the extracellular matrix environment, and utilizing a safe non-viral gene delivery tool. However, the main limitation of NPs is toxicity, which is related to their size, shape, aspect ratio, and surface charge. Currently, there have been many animal models proving NPs' potential in treating CVD, but no extensive applications of stem-cell therapy using NPs are available in clinical practice. In conclusion, NPs might have significant potential uses in clinical trials of CVD in the future, thereby meeting the changing needs of individual patients worldwide.

show abstract

The influence of peripheral arterial disease on lower limb surface myoelectric signals in patients living with type II diabetes mellitus

Cited by 6 publications

References 20 publications

Effects of intermittent claudication due to arterial disease on pain-free gait

Effects of intermittent claudication due to arterial disease on pain-free gait

Sarcopenia and peripheral arterial disease: a systematic review

The Roles of Nanoparticles in Stem Cell-Based Therapy for Cardiovascular Disease

Contact Info

Product

Resources

About